仁度生物
(688193)
| 流通市值：15.39亿 | | | 总市值：19.49亿 |
| 流通股本：3163.83万 | | | 总股本：4006.99万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 81,242,468.3 | 40,684,805.73 | 177,351,527.35 | 130,643,714.19 |
| 营业收入 | 81,242,468.3 | 40,684,805.73 | 177,351,527.35 | 130,643,714.19 |
| 二、营业总成本 | 88,783,400.31 | 44,161,459.69 | 189,591,775.01 | 135,834,212.99 |
| 营业成本 | 17,680,776.11 | 9,487,188.86 | 36,380,047.14 | 25,620,656.61 |
| 税金及附加 | 931,482 | 309,751.22 | 1,007,232.85 | 739,806.32 |
| 销售费用 | 40,134,358.55 | 20,123,462.89 | 89,862,202.43 | 63,481,069.09 |
| 管理费用 | 14,156,285.32 | 6,373,429.73 | 29,403,124.84 | 21,655,552.53 |
| 研发费用 | 16,679,648.87 | 8,247,774.22 | 39,165,424.68 | 29,996,309.8 |
| 财务费用 | -799,150.54 | -380,147.24 | -6,226,256.93 | -5,659,181.36 |
| 其中:利息费用 | 112,121.27 | 69,045.84 | 290,928.19 | 188,569.1 |
| 其中:利息收入 | 963,151.25 | 484,963.36 | 6,581,680.8 | 5,951,800.48 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,985,862.02 | 1,608,429.9 | -237,263.21 | 3,661,988.88 |
| 加:投资收益 | 4,904,494.32 | 1,941,053.63 | 11,174,071.57 | 3,618,280.83 |
| 资产处置收益 | 7,322.72 | - | 136,347.79 | - |
| 资产减值损失(新) | -905,130 | -643,374.72 | -2,722,757.78 | -1,925,192.93 |
| 信用减值损失(新) | -266,329.84 | -91,924.71 | -17,066,988.49 | -118,226.41 |
| 其他收益 | 2,690,562.37 | 1,346,215.8 | 6,371,943.48 | 4,456,961.17 |
| 营业利润平衡项目 | 0 | 0.01 | 0 | 0 |
| 四、营业利润 | 875,849.58 | 683,745.95 | -14,584,894.3 | 4,503,312.74 |
| 加:营业外收入 | 53,089.9 | 35,390.78 | 202,163.5 | 177,875.94 |
| 减:营业外支出 | 164,556.17 | 164,477.86 | 838,780.9 | 193,102.94 |
| 五、利润总额 | 764,383.31 | 554,658.87 | -15,221,511.7 | 4,488,085.74 |
| 减:所得税费用 | -1,273,582.67 | -666,272.27 | -7,409,323.88 | -183,111.19 |
| 六、净利润 | 2,037,965.98 | 1,220,931.14 | -7,812,187.82 | 4,671,196.93 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 2,037,965.98 | 1,220,931.14 | -7,812,187.82 | 4,671,196.93 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 2,037,965.98 | 1,220,931.14 | -7,812,187.82 | 4,671,196.93 |
| 扣除非经常损益后的净利润 | -4,282,814.89 | -2,183,877.18 | -19,559,897.22 | -3,170,004.37 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.03 | -0.2 | 0.12 |
| (二)稀释每股收益 | 0.06 | 0.03 | -0.2 | 0.12 |
| 八、其他综合收益 | -156,621.24 | -54,416.35 | 580,770.34 | -414,675.12 |
| 归属于母公司股东的其他综合收益 | -156,621.24 | -54,416.35 | 580,770.34 | -414,675.12 |
| 九、综合收益总额 | 1,881,344.74 | 1,166,514.79 | -7,231,417.48 | 4,256,521.81 |
| 归属于母公司股东的综合收益总额 | 1,881,344.74 | 1,166,514.79 | -7,231,417.48 | 4,256,521.81 |
| 公告日期 | 2025-08-30 | 2025-04-30 | 2025-04-30 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |